Treatment persistence with basal insulin in adults with T2D

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

Treatment persistence³

Toujeo^® (insulin glargine 300 Units/mL) was associated with better treatment persistence compared with insulin glargine 100 U/mL or insulin detemir in people with T2D.

The treatment persistence and hospitalisation retrospective analysis identified 181,263 people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.³

Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.³

Diabetes Products